Skip to main content

Mark Frame

Analyst

TD Cowen

Equibles does not estimate personal net worth.

About Mark Frame

Mark Frame is recorded as Analyst at TD Cowen. Mark Frame has spoken on 1 earnings call and 1 other investor event across 2 companies, most recently for Revolution Medicines, Inc. on May 6, 2026. Those appearances were for Revolution Medicines, Inc. (RVMD) and Nektar Therapeutics (NKTR). The companies whose calls Mark Frame spoke on are classified in the Healthcare sector.

Mark Frame on recent calls

“Maybe following up a little bit on Corey's question earlier, just on the Zoldan RASA plus Drax and RASA combo, can you maybe speak to the 309 design, particularly in light of the 302 finding and, you know, the survival data, I mean, looking better than anything we've ever seen, even in first line, just why is 309…”
Analyst — TD Cowen, Revolution Medicines, Inc. Q1 FY2026 Earnings Call ·
“Maybe I recognize some of this will get informed by seeing some of that off-treatment data, but just for the company, can you kind of walk through your current assumptions on how you would approach kind of maintenance dosing and then for the physician similarly you know how how are you expecting to use this in the…”
Analyst — TD Cowen, Analyst and Investor Event with Alopecia Areata Experts ·

Affiliation history

  • TD Cowen

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity